Myoclonic Epilepsy Clinical Trials

Find Myoclonic Epilepsy Clinical Trials Near You

EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome

Status: Active_not_recruiting
Location: See all (61) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 17
Healthy Volunteers: f
View:

• Patients must be ≥2 and \<18 years of age.

• Patients must have a clinical diagnosis of DS confirmed by the Epilepsy Study Consortium, Inc. (ESCI) and as defined by:

• Onset, prior to 12 months (inclusive, \<13 months), of age, of recurrent focal with motor signs, hemiclonic, or generalized tonic-clonic seizures. No other known etiology causing clinical DS manifestations..

• Patient must have a documented pathogenic, likely pathogenic variant, or variant of uncertain significance in the sodium voltage-gated channel type 1 alpha subunit (SCN1A) gene. Patients who have SCN1A testing results of Negative (no variants identified) cannot be randomized.

• Patient must experience the required number of major motor seizures during the 6-week Observation Period. Major motor seizure types included are Seizure types included in counts are Hemiclonic, Focal with Motor Signs, Focal to Bilateral Tonic-Clonic, Generalized Tonic-Clonic, Tonic, Tonic/Atonic (Drop Attacks with fall or risk of fall), and Bilateral Clonic.

• Patient must have used at least 2 prior interventions for seizures. These can include anti-seizure medications (ASMs), ketogenic diet and/or vagus nerve stimulation (VNS) with either lack of adequate seizure control or discontinued due to an AE(s). These interventions can be ongoing therapies.

• Patient must be taking at least one ASM. Benzodiazepines or ASMs used on a standing basis (i.e., not as needed \[PRN\]) for any indication will be considered an ASM.

• Patients' maintenance ASMs and interventions for seizures (i.e., ketogenic diet or VNS), as well as any marijuana- or cannabinoid-based products, must have been stable (unless adjusted for weight) during the Baseline Period.

Locations
United States
Arkansas
Arkansas Children's Hospital
Little Rock
Arizona
Phoenix Children's Hospital
Phoenix
California
Cedars Sinai Medical Center
Los Angeles
Children's Hospital of Orange County
Orange
USCF Medical Center
San Francisco
Colorado
Children's Hospital Colorado
Aurora
Washington, D.c.
Children's National Medical Center
Washington D.c.
Florida
Nemours Children's Health
Jacksonville
Nicklaus Children's Hospital
Miami
Advent Health Neuroscience Research Institute
Orlando
Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago
Massachusetts
Boston Children's Hospital
Boston
Massachusetts General Hospital
Boston
Michigan
CS Mott Children's Hospital
Ann Arbor
Minnesota
Mayo Clinic
Rochester
North Carolina
University of North Carolina at Chapel Hill
Chapel Hill
Duke University Health System
Durham
New York
NYU Langone Health
New York
Weill Cornell Medicine
New York
University of Rochester Medical Center
Rochester
Ohio
Cleveland Clinic
Cleveland
Nationwide Children's Hospital
Columbus
Oregon
Oregon Health & Science University (OHSU)
Portland
Tennessee
LeBonheur Children's Hospital
Memphis
Texas
Cook Children's Medical Center
Fort Worth
Texas Children's Hospital
Houston
Utah
University of Utah Primary Children's Hospital
Salt Lake City
Virginia
UVA Health
Charlottesville
Other Locations
China
Peking University First Hospital
Beijing
The Second Affiliated Hospital of Guangzhou Medical university
Guangzhou
Wuhan Children's Hospital
Wuhan
France
Hôpital de la Timone
Marseille
Hôpital Necker - Enfants Malades
Paris
Hôpital Robert Debré - Paris
Paris
Germany
Charité - Campus Virchow-Klinikum
Berlin
Universitaetsklinikum Bonn AoeR
Bonn
Universitaetsklinikum Frankfurt Goethe-Universitaet
Frankfurt
Universitaetsklinikum Freiburg
Friedberg
Universitaetsklinikum Heidelberg
Heidelberg
Integriertes Sozialpaediatrisches Zentrum
München
Italy
Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
Florence
Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS
Genova
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma
Ospedale Pediatrico Bambino Gesù
Roma
Japan
Fukuoka Children's Hospital
Fukuoka
Hokkaido University Hospital
Hokkaido
Kyoto University Hospital
Kyoto
Nagoya University Hospital
Nagoya
National Hospital Organization Nishi Niigata Central Hospital
Niigata
Okayama University Hospital
Okayama
Osaka City General Hospital
Osaka
Jichi Medical University Hospital
Shimotsuke
NHO Shizuoka
Shizuoka
National Center of Neurology and Psychiatry
Tokyo
Yokohama City University Medical Center
Yokohama
Spain
Hospital Blua Sanitas Valdebebas
Madrid
Hospital Ruber Internacional
Madrid
Clinica Universidad de Navarra
Pamplona
United Kingdom
Royal Hospital for Children
Glasgow
Great Ormond Street Hospital for Children
London
Sheffield Children's Hospital
Sheffield
Time Frame
Start Date: 2025-06-04
Completion Date: 2028-10
Participants
Target number of participants: 170
Treatments
Experimental: Zorevunersen
Eligible patients will be randomly assigned in a 1:1 ratio to zorevunersen:sham in Treatment Period 1 (approximately 52 weeks). Upon the completion of Treatment Period 1 all eligible patients, will enter Treatment Period 2 and receive zorevunersen, regardless of initial treatment assignment.
Sham_comparator: Sham Comparator
Eligible patients will be randomly assigned in a 1:1 ratio to zorevunersen:sham
Sponsors
Leads: Stoke Therapeutics, Inc

This content was sourced from clinicaltrials.gov